These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27729503)

  • 1. Evaluation of Parameters Impacting Drug Susceptibility in Intracellular Trypanosoma cruzi Assay Protocols.
    Yang G; Lee N; Ioset JR; No JH
    SLAS Discov; 2017 Feb; 22(2):125-134. PubMed ID: 27729503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease.
    Riley J; Brand S; Voice M; Caballero I; Calvo D; Read KD
    PLoS Negl Trop Dis; 2015 Sep; 9(9):e0004014. PubMed ID: 26394211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development.
    Moraes CB; Giardini MA; Kim H; Franco CH; Araujo-Junior AM; Schenkman S; Chatelain E; Freitas-Junior LH
    Sci Rep; 2014 Apr; 4():4703. PubMed ID: 24736467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain.
    Guedes-da-Silva FH; Batista DG; Da Silva CF; De Araújo JS; Pavão BP; Simões-Silva MR; Batista MM; Demarque KC; Moreira OC; Britto C; Lepesheva GI; Soeiro MN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
    Engel JC; Ang KK; Chen S; Arkin MR; McKerrow JH; Doyle PS
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3326-34. PubMed ID: 20547819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi.
    Soeiro Mde N; de Souza EM; da Silva CF; Batista Dda G; Batista MM; Pavão BP; Araújo JS; Aiub CA; da Silva PB; Lionel J; Britto C; Kim K; Sulikowski G; Hargrove TY; Waterman MR; Lepesheva GI
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4151-63. PubMed ID: 23774435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection.
    Guedes-da-Silva FH; Batista DG; da Silva CF; Meuser MB; Simões-Silva MR; de Araújo JS; Ferreira CG; Moreira OC; Britto C; Lepesheva GI; Soeiro Mde N
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7564-70. PubMed ID: 26416857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Image-Based Assay for Trypanosoma cruzi Intracellular Forms.
    Eufrásio AG; Cordeiro AT
    Methods Mol Biol; 2020; 2116():773-780. PubMed ID: 32221954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit.
    Chen CK; Doyle PS; Yermalitskaya LV; Mackey ZB; Ang KK; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2009; 3(2):e372. PubMed ID: 19190730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dialkylimidazole inhibitors of Trypanosoma cruzi sterol 14α-demethylase as anti-Chagas disease agents.
    Suryadevara PK; Racherla KK; Olepu S; Norcross NR; Tatipaka HB; Arif JA; Planer JD; Lepesheva GI; Verlinde CL; Buckner FS; Gelb MH
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6492-9. PubMed ID: 24120539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency.
    Calvet CM; Vieira DF; Choi JY; Kellar D; Cameron MD; Siqueira-Neto JL; Gut J; Johnston JB; Lin L; Khan S; McKerrow JH; Roush WR; Podust LM
    J Med Chem; 2014 Aug; 57(16):6989-7005. PubMed ID: 25101801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity.
    Franco CH; Warhurst DC; Bhattacharyya T; Au HYA; Le H; Giardini MA; Pascoalino BS; Torrecilhas AC; Romera LMD; Madeira RP; Schenkman S; Freitas-Junior LH; Chatelain E; Miles MA; Moraes CB
    Int J Parasitol Drugs Drug Resist; 2020 Aug; 13():107-120. PubMed ID: 32688218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
    Ferreira de Almeida Fiuza L; Peres RB; Simões-Silva MR; da Silva PB; Batista DDGJ; da Silva CF; Nefertiti Silva da Gama A; Krishna Reddy TR; Soeiro MNC
    Eur J Med Chem; 2018 Apr; 149():257-268. PubMed ID: 29501946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection.
    Calvet CM; Choi JY; Thomas D; Suzuki B; Hirata K; Lostracco-Johnson S; de Mesquita LB; Nogueira A; Meuser-Batista M; Silva TA; Siqueira-Neto JL; Roush WR; de Souza Pereira MC; McKerrow JH; Podust LM
    PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006132. PubMed ID: 29281643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade.
    De Rycker M; Thomas J; Riley J; Brough SJ; Miles TJ; Gray DW
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004584. PubMed ID: 27082760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery.
    Ekins S; de Siqueira-Neto JL; McCall LI; Sarker M; Yadav M; Ponder EL; Kallel EA; Kellar D; Chen S; Arkin M; Bunin BA; McKerrow JH; Talcott C
    PLoS Negl Trop Dis; 2015; 9(6):e0003878. PubMed ID: 26114876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Candidate VT-1161's Antiparasitic Effect In Vitro, Activity in a Murine Model of Chagas Disease, and Structural Characterization in Complex with the Target Enzyme CYP51 from Trypanosoma cruzi.
    Hoekstra WJ; Hargrove TY; Wawrzak Z; da Gama Jaen Batista D; da Silva CF; Nefertiti AS; Rachakonda G; Schotzinger RJ; Villalta F; Soeiro Mde N; Lepesheva GI
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1058-66. PubMed ID: 26643331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
    Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
    Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lead identification to clinical candidate selection: drugs for Chagas disease.
    Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
    J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
    de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
    Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.